Quest Diagnostics Stock (DGX) Likely to Remain Under Pressure until December 2025

Quest Diagnostics (Ticker: DGX) was one of the standout performers following the COVID-19 market crash in 2020, soaring nearly 75% within just a few months after the March 2020 low.

Since then, DGX has continued to show decent relative strength — but that may be changing.

According to the latest forecast from EquiPredict Analytics, DGX is expected to come under pressure and remain out of favor with Wall Street into late 2025. Our models suggest a bearish outlook through December 2025, with potential opportunities arising only after this period.

View the DGX forecast chart below:

Want more market-leading insights like this?

Sign up for the free quarterly market forecast from EquiPredict Analytics to receive our latest stock projections and cycle-based analysis.